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Introduction

Table 1: Summary of clinicopathologic characteristics of patients with positive LNs on ALND

• The recently presented RxPONDER
trial demonstrated that
postmenopausal patients with
hormone receptor-positive
(HR+), human epidermal growth factor
receptor 2-negative (HER2-) breast
cancer (BC) with 1-3 positive axillary
lymph nodes (LN) and a low Oncotype
DX Recurrence Score (≤25)
may potentially forgo chemotherapy.
• A method to accurately assess the
extent of axillary LN involvement is
needed.

• LN burden is typically determined
through complete axillary lymph
node dissection (ALND) for
patients who are clinically nodepositive and undergoing
upfront surgery.

1 LN on ALND

2 LN on ALND

3 LN on ALND

>3 LN on ALND

Total (n=157)

n=42

n=33

n=23

n=59

Median Age [years (range)]

59 (36-88)

60 (30-81)

54 (31-84)

58 (33-86)

Mean Tumor Size [cm (range)]

2.93 (1.10-7.00) 2.92 (0.80-4.50) 2.80 (1.10-4.00) 2.78 (0.70-5.00)

Histology (n=152)
IDC (n=113)

28 (25)

25 (22)

16 (14)

44 (39)

ILC (n=30)

8 (27)

5 (17)

7 (23)

10 (33)

Other (n=9)

6 (67)

3 (33)

0 (0)

0 (0)

1 (n=17)

6 (35)

2 (12)

4 (24)

5 (29)

2 (n=105)

27 (26)

23 (22)

16 (15)

39 (37)

3 (n=36)

9 (25)

9 (25)

3 (8)

15 (42)

• Pearson's correlation test revealed no
statistically significant association
between pathologically positive LNs
and median age, tumor size, or size of
index LN found on preoperative US.

Histologic Grade (n=158)

• US prediction of >3 LNs on ALND has
a false negative rate of 96.6%.

• Only 2 patients had >3 suspicious LNs
identified on US compared to 59
patients with >3 truly positive LNs.

Molecular Classification (n=86)
Luminal A (n=58)

16 (28)

11 (19)

10 (17)

21 (36)

Luminal B (n=28)

9 (32)

5 (18)

2 (7)

12 (43)

16 (20)

11 (14)

16 (20)

37 (46)

6 (8)

19 (27)

LVI (n=150)
% Identified (n=80)

% Not identified (n=70)
25 (36)
19 (29)
Data are expressed as n (%) unless otherwise specified

Limitations

• ALND may be overtreatment
for patients with limited axillary nodal
Figure 1: Number of suspicious LNs on US Figure 2: Number of pathologically positive LNs
burden.
versus number of positive LNs on ALND

given (A) 1, (B) 2, and (C) 3+ suspicious LNs on
US

Aim

(A)

• To analyze potential associations
between clinicopathologic factors
and number of pathologically
positive LNs in patients with clinically
axillary node-positive (cN1),
HR+/HER2- BC who underwent
upfront ALND.

Patients with HR+, HER2-, cN1 BC
who had undergone ALND were
identified from MDACC patient
records between 2002 and 2016.

•

Clinical characteristics based on
imaging and physical examination
were examined and
subsequently compared with
pathology.

•

Descriptive statistics were
performed, and variables were
assessed for association using
Chi-square analysis and Pearson's
correlation test.

•

This study was limited due to the
scope of analyses.

•

Small sample size may have
precluded identification of meaningful
associations.

Conclusion
• Preoperative US to determine extent
of LN involvement has a high false
negative rate when confirmed by
ALND.

• Individual clinicopathologic
features cannot be used to
predict the extent of LN involvement in
ALND. Multivariate studies are in
progress to evaluate whether
these clinicopathologic features can
(C)
be used in combination to
predict the extent of axillary nodal
involvement.

Methods
•

• Chi-square analysis revealed no
statistically significant association (p >
0.05) between number of
pathologically positive LNs and
histology, race, hormone receptor
expression, histologic grade, or LN
palpability on a physical exam.

(B)
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Table 3: Association between US nodal burden and nodal features on US and pathology

Mean size index LN on US (cm)
Median # positive LNs on ALND
Mean largest LN metastasis on ALND (cm)

1-2 Suspicious LNs
on US

3+ Suspicious LNs
on US

1.71
2
1.53

1.94
3
1.42
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